Bisphosphonates: Reducing the risk of skeletal complications from bone metastasis

Breast

Volumn 16, Issue SUPPL. 3, 2007, Pages 16-20

  Costa, L ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Bisphosphonate; Bone metastases; Breast cancer; Skeletal related event; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ADVANCED CANCER; ARTICLE; BONE CANCER; BONE DISEASE; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BREAST CANCER; CLINICAL TRIAL; DEATH; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HUMAN; INCIDENCE; INDIGESTION; JAW DISEASE; LONG TERM CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK REDUCTION;

EID: 36649001116     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.10.005     Document Type: Article

References (40)

1. Major P.P., and Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol 25 suppl. 1 (2002) S10-S18
2. Pavlakis N., Schmidt R.L., and Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 3 (2005) 1-38
3. Kohno N., Aogi K., Minami H., et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23 (2005) 3314-3321
4. Hortobagyi G.N., Theriault R.L., Porter L., et al., Protocol 19 Aredia Breast Cancer Study Group. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335 (1996) 1785-1791
5. Hortobagyi G.N., Theriault R.L., Lipton A., et al., Protocol 19 Aredia Breast Cancer Study Group. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16 (1998) 2038-2044
6. Body J.J., Diel I.J., Lichinitser M.R., et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14 (2003) 1399-1405
7. Body J.J., Diel I.J., Bell R., et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111 (2004) 306-312
8. Kristensen B., Ejlertsen B., Groenvold M., Hein S., Loft H., and Mouridsen H.T. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 246 (1999) 67-74
9. Paterson A.H.G., Powles T.J., Kanis J.A., McCloskey E., Hanson J., and Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11 (1993) 59-65
10. Tubiana-Hulin M., Beuzeboc P., Mauriac L., et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 88 (2001) 701-707
11. Conte P.F., Rosen L.S., Gordon D., Zheng M., and Hei Y.-J. Zoledronic acid is superior to pamidronate in patients with breast cancer and multiple myeloma: analysis of patients at high risk for skeletal complications. Ann Oncol 15 suppl. 3 (2004) iii124 [Abstract 463PD]
12. Costa L, Chen Y-M. Breast cancer patients without pain are at risk for skeletal-related events and may have better outcomes with zoledronic acid compared with pamidronate. Presented at: The 29th annual San Antonio breast cancer symposium. San Antonio, TX, December 14-17, 2006 [Abstract 1071].
13. Soloway M.S., Hardeman S.W., Hickey D., et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61 (1988) 195-202
14. Martin T.J., and Moseley J.M. Mechanisms in the skeletal complications of breast cancer. Endocr Relat Cancer 7 (2000) 271-284
15. Zheng M, Rosen L, Gordon D, et al. Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases. Presented at: Primary therapy of early breast cancer ninth international conference. St. Gallen, Switzerland, January 26-29, 2005 [Poster 104].
16. Ali S.M., Esteva F.J., Hortobagyi G., et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 19 (2001) 3434-3437
17. Brown J.E., Cook R.J., Major P., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97 (2005) 59-69
18. Coleman R.E., Major P., Lipton A., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23 (2005) 4925-4935
19. Lipton A, Cook RJ, Coleman RE, Major P, Shirina N. Prognostic significance of persistently elevated N-telopeptide levels in patients with bone metastases from solid tumors. Presented at 31st European society for medical oncology (ESMO) Congress. Istanbul, Turkey, 29 September-3 October, 2006 [Abstract 870P].
20. Coleman R.E. Bisphosphonates in breast cancer. Ann Oncol 16 (2005) 687-695
21. Farrugia M.C., Summerlin D.J., Krowiak E., et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 116 (2006) 115-120
22. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
23. Dimopoulos M.A., Kastritis E., Anagnostopoulos A., et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91 (2006) 968-971
24. Hoff AO, Toth BB, Altundag K, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. 42nd Annual meeting of the American society of clinical oncology. Atlanta, Georgia, USA, 2006 [Abstract 8528].
25. Mehrotra B., and Ruggiero S. Bisphosphonate complications including osteonecrosis of the jaw. Hematology Am Soc Hematol Educ Program (2006) 356-360
26. Migliorati C.A., Siegel M.A., and Elting L.S. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 7 (2006) 508-514
27. Ruggiero S., Gralow J., Marx R.E., et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2 (2006) 7-14
28. Weitzman R., Sauter N., Eriksen E.F., et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 62 (2007) 148-152
29. Rosen L., Harland S.J., and Oosterlinck W. Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors. Am J Clin Oncol 25 suppl. 1 (2002) S19-S24
30. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879-882
31. Rosen L.S., Gordon D., Tchekmedyian N.S., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100 (2004) 2613-2621
32. Hillner B.E., Ingle J.N., Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 (2003) 4042-4057
33. Kyle R.A., Yee G.C., Somerfield M.R., et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25 (2007) 2464-2472
34. Green J.R. Antitumor effects of bisphosphonates. Cancer 97 suppl. (2003) 840-847
35. Rack B.K., Janni W., Schoberth A., et al. Effect of zoledronate on persisting isolated tumor cells (ITC) in the bone marrow (BM) of patients without recurrence of early breast cancer. Proc Am Soc Clin Oncol 23 suppl. (2004) 834 [Abstract 9515]
36. Santini D., Vincenzi B., Battistoni F., et al. In vivo perspective study about the effects of weekly low dose administration of zoledronic acid (ZA) on angiogenesis. J Clin Oncol 25 suppl. (2007) 152s [Abstract 3558]
37. Santini D., Vincenzi B., Dicuonzo G., et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9 (2003) 2893-2897
38. Mystakidou K., Katsouda E., Parpa E., Kelekis A., Galanos A., and Vlahos L. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 22 (2005) 195-201
39. University of Leeds Clinical Trials Research Unit. BISMARK Trial: cost-effective use of BISphosphonates in metastatic bone disease: a comparison of bone MARKer directed zoledronic acid therapy vs. a standard schedule. Available at: 〈http://www.leeds.ac.uk/medicine/nyctru/ProjectPage_Bismark.htm〉. Accessed September 4, 2007.
40. Tormey D.C., Gray R., Taylor 4th S.G., Knuiman M., Olson J.E., and Cummings F.J. Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer. NCI Monogr (1986) 75-80